Table 2 Drugs administered as first, second and third line prior to osimertinib

First-line treatment prior to osimertinib

151

100%

 Monotherapy

120

79.5%

 Gefitinib

51

33.8%

 Erlotinib

39

25.8%

 Afatinib

24

15.9%

 Cisplatin

2

1.3%

 Dacomitinib

2

1.3%

 Pembrolizumab

1

0.7%

 Pemetrexed

1

0.7%

 Combination (2 drugs)

27

17.9%

  Cisplatin + Pemetrexed

7

4.6%

  Cisplatin + Vinorelbine

6

4.0%

  Carboplatin + Pemetrexed

5

3.3%

  Bevacizumab + Erlotinib

2

1.3%

  Carboplatin + Vinorelbine

2

1.3%

  Gefitinib + Olaparib

2

1.3%

  Carboplatin + Paclitaxel

1

0.7%

  Cisplatin + Docetaxel

1

0.7%

  Cisplatin + Etoposide VP16

1

0.7%

 Combination (3 drugs)

4

2.6%

  Bevacizumab + Carboplatin + Paclitaxel

2

1.3%

  Bevacizumab + Cisplatin + Pemetrexed

2

1.3%

Second-line treatment prior to osimertinib

68

100%

 Monotherapy

40

58.8%

  Erlotinib

19

27.9%

  Gefitinib

9

13.2%

  Afatinib

7

10.3%

  Pemetrexed

2

2.9%

  Docetaxel

1

1.5%

  Gemcitabine

1

1.5%

  Rociletinib

1

1.5%

 Combination (2 drugs)

21

30.9%

  Carboplatin + Pemetrexed

9

13.2%

  Cisplatin + Pemetrexed

7

10.3%

  Bevacizumab + Erlotinib

1

1.5%

  Carboplatin + Etoposide VP16

1

1.5%

  Carboplatin + Paclitaxel

1

1.5%

  Gefitinib + Olaparib

1

1.5%

  Gefitinib + Pemetrexed

1

1.5%

 Combination (3 drugs)

6

8.8%

  Bevacizumab + Carboplatin + Paclitaxel*

4

5.9%

  Bevacizumab + Cisplatin + Pemetrexed

1

1.5%

  Carboplatin + Erlotinib + Pemetrexed

1

1.5%

 Combination (4 drugs)

1

1.5%

  Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel**

1

1.5%

Third-line treatment prior to osimertinib

37

100%

 Monotherapy

23

62.2%

  Erlotinib

7

18.9%

  Afatinib

5

13.5%

  Gefitinib

3

8.1%

  Pemetrexed

3

8.1%

  Vinorelbine

2

5.4%

  Docetaxel

1

2.7%

  Nivolumab

1

2.7%

  Rociletinib

1

2.7%

 Combination (2 drugs)

12

32.4%

  Carboplatin + Pemetrexed

6

16.2%

  Docetaxel + Nintedanib

2

5.4%

  Afatinib + Cetuximab

1

2.7%

  Carboplatin + Paclitaxel

1

2.7%

  Cisplatin + Pemetrexed

1

2.7%

  Gemcitabine + Paclitaxel

1

2.7%

 Combination (3 drugs)

2

5.4%

  Atezolizumab + Carboplatin + Paclitaxel

1

2.7%

  Carboplatin + Erlotinib + Pemetrexed

1

2.7%